New FDA-Approved Treatment for Rosacea: Effective Relief for Inflammatory Symptoms

Overview of Rosacea | How This Treatment Stands Out | Results from Clinical Trials | Usage and Important Safety Information | What This Means for Rosacea Patients

The FDA has approved Emrosi, a 40mg Minocycline Hydrochloride Extended Release capsule, for treating inflammatory lesions of rosacea in adults.

This novel treatment targets the pimple-like bumps associated with rosacea by reducing inflammation and swelling. Its extended-release formulation combines 10 milligrams for immediate action and 30 milligrams released gradually over time, ensuring consistent drug levels in the body.

This approach minimizes side effects and reduces the need for multiple daily doses, offering a promising new option for rosacea management.

Overview of Rosacea

Rosacea lesions on the chin with small red spots, flushing, and occasional burning or itching

Rosacea is a chronic inflammatory skin condition that affects 10% of the population. It primarily affects the forehead, nose, chin and cheeks. Persistent facial erythema with or without edema, visible blood vessels, frequent flushing are the most common symptoms. Rosacea prevalence is high among individuals with fair skins.

Beyond its physical symptoms, rosacea has been shown to have a significant psychological impact. According to the National Rosacea Society surveys, 90% of patients say that their self-esteem and confidence have decreased as a result of their condition, and 41% say that it has made them avoid social situations or cancel engagements. Furthermore, 51% of those with severe symptoms reported missing work due to their illness, and 88% claimed the disorder had negatively impacted their professional interactions.

How This Treatment Stands Out

Emrosi is uniquely formulated with 40 milligrams of Minocycline Hydrochloride, where 10 milligrams act immediately and 30 milligrams are released gradually over time. This extended-release mechanism ensures a steady concentration of the drug in the body, enhancing its effectiveness in reducing redness and inflammatory bumps while lowering the risk of side effects. By decreasing the need for multiple daily doses, Emrosi offers a more convenient option for rosacea patients.

Results from Clinical Trials

The positive results of the two randomized, double blind, active and placebo-controlled Phase 3 clinical trials for the treatment of rosacea has supported to gain the Emrosi’s approval. It has fulfilled all the co-primary and secondary objectives in the Phase 3 clinical studies. The participants of the clinical trial have successfully finished the 16-week course of treatment without experiencing any serious safety concerns except dyspepsia by 1% of the participants. According to the Investigator’s Global Assessment, it significantly outperformed the current standard-of-care (Oracea) and placebo in terms of treatment success and reduction in the number of total inflammatory lesions.

Usage and Important Safety Information

Dosage

• Recommended Dosage: One capsule taken orally once daily.
• Effectiveness: Higher doses do not provide additional benefits for rosacea treatment.
• Administration:
  • Can be taken with or without food.
  • Food may reduce the risk of ulceration and esophageal discomfort.
  • Important: Swallow the extended-release capsule whole. Do not crush or chew.

Contraindications

• Patients with a history of hypersensitivity to tetracyclines should avoid Emrosi.

Special Precautions

• Pregnancy and Children:
  • Avoid use during the second and third trimesters of pregnancy.
  • Not recommended for infants and children under eight years old due to risks of:
    • Irreversible suppression of bone growth.
    • Permanent teeth discoloration.
• Sunlight Exposure:
  • Limit or avoid exposure to natural or artificial sunlight. (e.g., tanning beds, Phototherapy Devices, UV lamps)
  • Tetracycline-class antibiotics can induce hyperpigmentation.

Side Effects

• Common Side Effect: Mild stomach discomfort.
• Other Concerns: Consult a healthcare provider for any issues beyond mild discomfort.

What This Means for Rosacea Patients

Emrosi provides a new option for managing rosacea symptoms, particularly for those struggling with inflammatory bumps and redness. Its unique extended-release formulation allows for consistent treatment, reducing flare-ups and improving overall skin clarity. By addressing the physical symptoms effectively, Emrosi may also help restore confidence and improve quality of life for rosacea patients. However, individual responses to the treatment may vary, and patients are encouraged to consult with their dermatologist for personalized advice.

Availability Timeline

The initial supply of Emrosi, which Journey Medical is finishing up for the US market, will be ready late in the first quarter or early in the second quarter of 2025. Journey Medical will implement a launch strategy in accordance with the authorized label to propel Emrosi towards becoming the new oral standard of therapy for adults with rosacea.